Expansion in biologics innovation and cost-sensitive healthcare systems is boosting uptake of biosimilars. Patent cliffs for major drugs such as monoclonal antibodies drive competition. The market is advancing in oncology, autoimmune, and diabetes segments, supported by regulatory reforms and increased manufacturing capacity. https://www.einpresswire.com/article/833505102/biosimilars-and-biologics-market-growth-driven-by-patent-expiries-innovation-datam-intelligence